Genetic severity markers in multiple sclerosis

Details Genetic severity markers in multiple sclerosis Genetic severity markers in multiple sclerosis

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01)

Patent

CA 2749870

The present invention relates to the use of SNPs in predicting susceptibility and/or severity of Multiple Sclerosis in an individual. The SNPs are located in the introns of the glycosylation enzymes MGAT5 and XYLTl, 3' of HIFlAN, within in-trons of MEGF11, FGF14, PDE9A and CDH13 and within desert regions of 4q34 and 17p13.

La présente invention concerne l'utilisation de SNP pour prévoir la sensibilité à et/ou la gravité de la sclérose en plaques chez un individu. Les SNP sont situés dans les introns des enzymes de glycosylation MGAT5 et XYLTI, 3' de HIFIAN, dans les introns de MEGF11, FGP14, PDE9A et CDH13 et dans les régions désertes de 4q34 et 17p13.

Affiliated with

Also associated with

Rating

Genetic severity markers in multiple sclerosis does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Genetic severity markers in multiple sclerosis, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genetic severity markers in multiple sclerosis will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-2091010